Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 22,663

Document Document Title
WO/2018/189212A1
The invention relates to non-deliquescent acid addition salts of elagolix with strong acids, for example selected from the group consisting of sulfuric acid and hydrochloric acid, to processes for their preparation and to a pharmaceutica...  
WO/2018/189213A1
The invention relates to an amorphous solid dispersion comprising elagolix sodium and at least one silicon-based inorganic compound and to a process for preparing the same. Furthermore, it relates to a pharmaceutical composition comprisi...  
WO/2018/191522A1
The present disclosure provides methods of treating polycystic ovary syndrome (PCOS) with tetrahydro-iso-alpha acid (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof, in part...  
WO/2018/184523A1
A composition comprising a grape seed extract and a black tea extract. The composition can increase testosterone secretion more effectively than a single component, and can be used for preparing pharmaceutical compositions, foods, health...  
WO/2018/185131A2
This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, ...  
WO/2018/184115A1
Compounds comprising quinazolinone derivatives and methods of identification and use of imaging agents. The compounds have the general formula I: wherein R2 is selected from halogen, halosubstituted alkyl, alkyl, hydroxyl-alkyl, and amin...  
WO/2018/186366A1
The present invention addresses the problem of providing a novel cyclin-dependent kinase 8 and/or 19 inhibitor that is useful as an anticancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor that c...  
WO/2018/186953A1
Described are macro-capsules and barriers that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.  
WO/2018/177993A1
The invention relates, inter alia, to compounds of general formula (I). The invention also relates to methods for synthesizing the compounds of formula (I). The compounds according to the invention are in particular suitable for controll...  
WO/2018/177381A1
The invention relates to the field of pharmaceutical chemistry, and particularly relates to a compound represented by formula (I), a preparation method thereof, and a medical use thereof. In the compound represented by formula (I), a lac...  
WO/2018/174283A1
Provided is a sustained-release formulation of evocalcet or a pharmacologically acceptable salt thereof. A polyethylene glycol derivative of evocalcet or a pharmacologically acceptable salt thereof is used.  
WO/2018/168879A1
[Problem] To provide a composition having an estrogen-like action which comprises a hot water extract of Sparassis crispa mycelia.  
WO/2018/166468A1
Disclosed are an IgG-like long-acting immune fusion protein and the use thereof. The IgG-like long-acting immune fusion protein consists of an effector molecule and a constant region of an IgG antibody, and the effector molecule is linke...  
WO/2018/166494A1
The present disclosure relates to the use of a compound as shown in formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating diabetes mellitus, or the use of same in the...  
WO/2018/165933A1
Polypeptide for regulating saccharometabolism and uses thereof in the preparation of drugs for treating diseases related to saccharometabolism. The polypeptide can reduce blood sugar, can promote insulin secretion, can be used in the pre...  
WO/2018/159522A1
Provided is a food composition for preventing or alleviating metabolic syndrome, the food composition containing, as active ingredients, a 67 kDa laminine receptor (67LR) agonist and a sulfur-containing compound found from an allium plan...  
WO/2018/157202A1
The present invention is a delivery system for sublingual and/or buccal delivery comprising at least one functional oil (i.e. acting as an oil delivery base); at least one surfactant; and at least one pharmaceutically active agent. The i...  
WO/2018/155622A1
By suppressing the loss of living cells or living tissue during the production of a PVA gel that contains living cells or living tissue, the present invention addresses the problem of supplying a cell- or tissue-embedding device that has...  
WO/2018/153849A1
The present invention relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relate...  
WO/2018/148666A1
It is disclosed herein that a FAK inhibitor induces conversion of acinar cells into beta cells. Methods are provided for increasing beta cell proliferation by administering an effective amount of a FAK inhibitor to a subject in need ther...  
WO/2018/147300A1
Provided is a somatostatin receptor subtype 2 agonist. A compound disclosed in the present invention that is represented by general formula (I) (wherein each symbol has the same meaning as defined in the description) or a salt thereof is...  
WO/2018/146473A1
The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysacchar...  
WO/2018/136890A1
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLR...  
WO/2018/130174A1
Disclosed are a pyrrolo[2,3-c]pyridine derivative, a preparation method therefor, and use thereof in medicine. Specifically, disclosed are a pyrrolo[2,3-c]pyridine derivative as represented by general formula (1), a preparation method th...  
WO/2018/129395A1
The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.  
WO/2018/122409A1
Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions...  
WO/2018/123910A1
[Problem] To provide a composition with which it is possible to promote increase in androgen. [Solution] Provided is a composition for promoting increase in androgen, and which contains compound K. This composition for promoting increase...  
WO/2018/124009A1
The purpose of the present invention is to provide a prophylactic or ameliorating agent for hypothermia which is effective against hypothermia. Specifically provided is a prophylactic or ameliorating agent for hypothermia which compris...  
WO/2018/118691A1
Disclosed herein are methods for determining inflammation in subjects. Also disclosed are methods for determining whether a subject has sepsis. The methods include determining methylation of preproinsulin DNA.  
WO/2018/114670A1
The present invention covers [4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-4- yl)methanone compounds of general formula (I): (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, interme...  
WO/2018/103726A1
Provided are a crystal form of a bromodomain protein inhibitor 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquin azolin-4(3H)-one represented by Formula I, a preparation method and a use thereof. The present invention belongs ...  
WO/2018/100776A1
Provided is a technique for decomposing a resveratrol glycoside, preferably decomposing a resveratrol glycoside and an isoflavone glycoside, and thus promoting aglycone production to thereby increase the absorbability thereof into a livi...  
WO/2018/099363A1
Provided is the use of an insulin-like growth factor-2 for preparing a pharmaceutical composition, wherein the pharmaceutical composition is used for (i) promoting the expression of the macrophage PD-L1, and/or (ii) inhibiting the expres...  
WO/2018/098501A1
The present disclosure provides methods and compositions for testosterone replacement therapy. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a the...  
WO/2018/091153A1
The present invention relates to novel substituted N-(3-fluoropropyl)-pyrrolidine compounds of formula (l-A): wherein R1 and R2 represent independently a hydrogen atom or a deuterium atom; A represents an oxygen or nitrogen atom; and SER...  
WO/2018/090851A1
Disclosed is the use of FBP aldolase in the preparation of a drug activating AMPK. Also disclosed are the uses of FBP aldolase in the preparation of a drug for inhibiting cholesterol synthesis, a drug for reducing fatty acid synthesis, a...  
WO/2018/078049A1
The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanoph...  
WO/2018/077795A1
The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising such compounds, for use for treating and/or preventing endometriosis.  
WO/2018/068120A1
The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: a compound; the use of said compound; a synthetic intermediate in the preparation of comp...  
WO/2018/071058A1
Embodiments of the disclosure concern methods and compositions for delivering therapeutic, diagnostic or interventional moieties, such as complex and simple entities such as biologies, including at least cells, for example. The methods e...  
WO/2018/066707A1
Provided are: a novel aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor; food and beverage products, pharmaceutical products, and cosmetic products which include said inhibitors; and a method for...  
WO/2018/060213A1
The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin r...  
WO/2018/060438A1
Further according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as in in vitro fertilization (IVF) or in an embryo transfer (ET) process. There are also methods for ...  
WO/2018/064238A1
The addition of a salt to an ALA formulation reduces the degree of burning or irritation from ALA exposure during administration. This is particularly useful for an oral dissolve form of administration due to the extended time of ALA exp...  
WO/2018/060212A1
The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt%. The invention further relates...  
WO/2018/060704A1
Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduct...  
WO/2018/060311A1
The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preve...  
WO/2018/055539A1
The invention relates to an aqueous pharmaceutical composition comprising: (a) from about 1 IU/ml to about 500 IU/ml of buffered insulin glargine, and (b) one or more pharmaceutically acceptable excipients, wherein the pharmaceutical com...  
WO/2018/053036A1
The present disclosure is directed to methods of administration of thyroid hormone receptor agonists. The disclosure provides methods wherein the activity of the given thyroid receptor agonists in ameliorating or curing obesity, hyperlip...  
WO/2018/046719A1
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes...  

Matches 1 - 50 out of 22,663